(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 10.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Incyte's revenue in 2026 is $4,813,105,000.On average, 28 Wall Street analysts forecast INCY's revenue for 2026 to be $1,105,100,495,187, with the lowest INCY revenue forecast at $986,717,905,278, and the highest INCY revenue forecast at $1,199,728,038,033. On average, 23 Wall Street analysts forecast INCY's revenue for 2027 to be $1,214,255,918,055, with the lowest INCY revenue forecast at $1,062,694,791,339, and the highest INCY revenue forecast at $1,452,591,679,497.
In 2028, INCY is forecast to generate $1,252,735,167,843 in revenue, with the lowest revenue forecast at $1,013,810,438,292 and the highest revenue forecast at $1,581,772,018,071.